tablets "Alzepil" are applied to symptomatic treatment of Alzheimer's disease from easy or moderate severity.

Structure

Active ingredient - donepezil (one tablet, coated, contains donepezil 5 mg).

Excipients: cellulose microcrystalline, the hydroxypropyl cellulose low-substituted magnesium stearate, a gipromelloz, the titan dioxide (E171), a macrogoal 400.

Contraindication

Hypersensitivity to donepezil, derivatives of piperidine or to any excipients of drug.

Route of administration

Adult patients and patients of advanced age. Treatment begin with a dose 5 mg/days (reception of 1 times a day). Alzepil it is necessary to accept inside in the evening, just before a dream. Doses of 5 mg/days should be observed within not less than one month to provide earlier clinical response to treatment by results of assessment and to reach equilibrium concentration of donepezil. After clinical assessment of treatment in a dose of 5 mg/days within one month it is possible to increase a dose of donepezil to 10 mg/days (reception of 1 times a day).

Maximum recommended daily dose makes 10 mg. The doses exceeding 10 mg/days in clinical trials did not study.

while the patient receives therapeutic advantage. Thus, the clinical advantage of donepezil should be estimated regularly. If proofs of therapeutic effect are not observed any more, it is necessary to consider a question of medicament withdrawal. The individual answer to donepezil cannot be predicted.

At cancellation of treatment observes gradual reduction of favorable effect of donepezil.

Feature of use

Pregnant

is not recommended to use medicament during pregnancy and feeding by a breast.

Alzepil is not recommended to apply

to children.

Drivers

Donepezil has the minimum or moderate impact on ability to run vehicles and to work with mechanisms. Dementia of altsgeymerovsky type can cause deterioration in ability to run motor transport or to work with mechanisms. Besides, donepezil can cause increased fatigue, dizziness and myotonia, generally in an initiation of treatment or at increase in a dose. The ability of the patients accepting donepezil to run motor transport or mechanisms has to be estimated by the doctor in accordance with the established procedure.

Overdose of inhibitors of cholinesterase can lead

to cholinergic crisis which is characterized by the severe nausea, vomiting, salivation raised by perspiration, bradycardia, arterial hypotonia, respiratory depression, collapse and spasms. The accruing muscle weakness is possible that it can lead to flying consequences in case of damage of respiratory muscles.

As well as at any to overdose, it is necessary to apply the general supporting actions. As antidote at overdose of donepezil it is possible to use tertiary anticholinergics, such as atropine.

Side effects

Most frequent side effects are diarrhea, muscular spasms, increased fatigue, nausea, vomiting and insomnia.

to Store

at a temperature not above 30 °C, out of children's reach.

Expiration date - 5 years.